ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2689 • ACR Convergence 2024

    Characterization of Alpha-1 Antitrypsin Function in ANCA-Associated Vasculitis

    Lynn Fussner1, Ivan Bilic2, Carol McAlear3, David Cuthbertson4, Jie Cheng5, Elise Chen5, Markus Weiller2, Ulrich Specks6 and Peter Merkel3, and for the Vasculitis Clinical Research Consortium, 1The Ohio State University, Columbus, OH, 2Takeda Pharmaceuticals, Vienna, Austria, 3University of Pennsylvania, Philadelphia, PA, 4University of South Florida, Tampa, FL, 5Takeda Pharmaceuticals, Cambridge, MA, 6Mayo Clinic, Rochester, MN

    Background/Purpose: Two separate genome-wide association studies demonstrated that polymorphisms in SERPINA1, encoding serine protease inhibitor alpha-1 antitrypsin (A1AT), are associated with increased risk of developing…
  • Abstract Number: 2688 • ACR Convergence 2024

    HLA-DRB4: A Novel Susceptibility Locus in Systemic Sclerosis Patients with Severe Calcinosis

    Sara Faghihi-Kashani1, srijana davluri2, Kamini Kuchinad3, Zuoming deng4, Faiza Naz4, Stefania Dell'Orso4, Zsuzsanna McMahan5, Laura Hummers6, Daniel Kastner7, Fredrick Wigley3, david fiorentino8, Christian Lood9, Ami Shah10, Lorinda Chung11 and Pravitt Gourh4, 1Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, 2Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, Sunnyvale, CA, 3Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, 4National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, 5UTHealth Houston Division of Rheumatology, Houston, TX, 6Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, 7National Human Genome Research Institute, Bethesda, MD, Bethesda, MD, 8Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, 9Division of Rheumatology, University of Washington, Seattle, WA, Seattle, WA, 10Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, 11Stanford University, Woodside, CA

    Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease. Class II HLA alleles have been reported to play an important role in SSc pathogenesis. Calcinosis, deposition of…
  • Abstract Number: 2692 • ACR Convergence 2024

    Transcriptomic Profiling of Kidney Biopsies Implicates Th17 and IL-17 in ANCA-Associated Vasculitis

    Ivana Stojkic1, Arnon Arazi2, Huijuan Song3, Pearlly Yan4, Estela Puchulu-Campanella3, Hubao Wang3, Lynn Fussner3, Brad Rovin3, Samir Parikh5, Stacy Ardoin6, Daniel Koboldt7, James Fitch7 and Salem Almaani8, 1Nationwide, Columbus, OH, 2Feinstein Institutes for Medical Research, Melrose, MA, 3The Ohio State University, Columbus, OH, 4The Ohio State University, Columbus, 5Ohio State University, Columbus, OH, 6Nationwide Children's Hospital, Columbus, OH, 7Steve and Cindy Rasmussen Institute for Genomic Medicine, Columbus, OH, 8The Ohio State University Medical Center, Columbus, OH

    Background/Purpose: ANCA-associated vasculitis (AAV) is a severe autoimmune disease targeting small vessels, with significant kidney involvement. Despite current therapies, up to 28% of patients progress…
  • Abstract Number: PP05 • ACR Convergence 2024

    Reunion with Forgotten Relationships and Memories

    Noriko Okochi1, Eiji Oishi2, Kaoru Mitsuyama3, Emi Sorimachi3, Shiho Bando4, Yuka Hirama5, Nobuyuki Yajima6 and Masaaki Mori7, 1Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, 2Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan, 3Institute of Neuropsychiatry, Tokyo, Tokyo, Japan, 4Ota-ku Children and Families Support Center, Ota-ku, Tokyo, Japan, 5Asada Ladies Clinic, Shinagawa, Japan, Tokyo, Japan, 6Showa-Universtiy of Medicine, Tokyo, Japan, 7Tokyo Medical and Dental University, Tokyo, Japan

    Background/Purpose: Paediatric rheumatic diseases are complex experiences for children.  For children whose language skills are still undeveloped, it is difficult for them to put their…
  • Abstract Number: PP04 • ACR Convergence 2024

    Involving Pediatric Patients in Their Own Care

    Whitney LaBar, Lupus and Allied Diseases Association, Pleasanton, CA

    Background/Purpose: When I was 14, I was diagnosed with thrombocytopenia, which led to more testing and a diagnosis of systemic lupus erythematosus (SLE). As a…
  • Abstract Number: PP01 • ACR Convergence 2024

    An OCEAN of Change: The Impact of an RA Diagnosis on My Big Five Personality Traits

    Laura Sambursky1 and Lauren Sambursky2, 1Patient, Sarasota, FL, 2Northeastern University, Boston, MA

    Background/Purpose: Until age 32, I was a healthy, confident, extraverted, and creative person. I moved hundreds of miles away for college and then earned a…
  • Abstract Number: PP03 • ACR Convergence 2024

    How Completing a Systematic Literature Review Improved How I Research My Own Rheumatoid Arthritis and Comorbidities

    Shelley Fritz, Global Healthy Living Foundation, Kalaheo, HI

    Background/Purpose: Twelve years ago, I was diagnosed with rheumatoid arthritis (RA). Initially, I was hopeful that the first biologic DMARD would slow the disease and…
  • Abstract Number: PP11 • ACR Convergence 2024

    Living Well with Chronic Illness: Decades with MCTD

    Carol KAMINSKI, HP (Hewlett Packard) Retired, Wilmington, NC

    Background/Purpose: In the fall of 1985, I was not feeling well. I attributed my tiredness, weakness and malaise to stress and carried on. Walking upstairs I…
  • Abstract Number: 2661 • ACR Convergence 2024

    Changes in Krebs Von Den Lungen 6 Levels (∆KL6) Predict Fibrosing Progression of Interstitial Lung Disease in Patients with an Underlying Connective Tissue Disease (CTD-ILD)

    Fredeswinda Romero-Bueno1, María Carmen Vegas-Sánchez2, lydia Abasolo Alcazar3, Mª Jesus Rodriguez Nieto2, Cristina Vadillo-Font4, M Asuncion Nieto5, Laura Cebrián6, Belén López-Muñiz6, Jesus Loarce Martos7, Juan Rigual8, hildegarda Godoy Tundidor9, Rosalía Laporta10, Irene Llorente-Cubas11, Gema Bonilla12, Luis Gomez Carrera13, Rosario García-Vicuña14, Ana Jaureguizar7, Jose Luis Morell Hita7, Claudia Valenzuela15 and Olga Sánchez-Pernaute16, and the NEREA Study group for Autoimmune ILD, 1Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, 2Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, 3IdISSC. HCSC, Madrid, Spain, 4Hospital Clinico S Carlos, Madrid, Spain, 5Hospital Clínico San Carlos, Madrid, Madrid, Spain, 6Hospital Universitario Infanta Leonor, Madrid, Spain, 7Hospital Universitario Ramón y Cajal - IRYCIS, Madrid, Spain, 8Ramón y Cajal University Hospital, Madrid, Madrid, Spain, 9Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, 10Hospital Universitario Puerta de Hierro, Madrid, Spain, 11Hospital Universitario de La Princesa, Madrid, Spain, 12H. Universitario La Paz, Madrid, Spain, 13Hospital Universitario La Paz, Madrid, Spain, 14Hospital Universitario de la Princesa, Madrid, Madrid, Spain, 15Hospital Universitario La Princesa, Madrid, Spain, 16Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain

    Background/Purpose: Krebs von den Lungen-6 (KL6) is a mucin-1 glycoprotein produced by type 2 alveolar epithelial cells , which increase at peripheral blood show a…
  • Abstract Number: 2664 • ACR Convergence 2024

    BCMA-targeted Bispecific T Cell-engager Therapy of Autoimmune Disease

    Laura Bucci1, Melanie Hagen2, Sebastian Boeltz2, Danae-Mona Noethling2, Tobias Rothe2, Maria Gabriella Raimondo1, Carlo Tur1, Andreas Wirsching1, Jochen Wacker1, Aline Bozec1, Georg Schett3 and Ricardo Grieshaber-Bouyer2, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 3Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: Targeting B cells and plasma cells is a key therapeutic strategy in autoimmune disease(AID). Therapy with CD19-targeted chimeric antigen receptor (CAR) T-cells and bi-specific…
  • Abstract Number: 2684 • ACR Convergence 2024

    Assessment of Skin in Patients with Systemic Sclerosis Using High Frequency Ultrasound : A Comparative Study with Histology and Clinical Parameters of Skin Disease

    Ruhani Desai1, Filemon Tan2, Minghua Wu3, Jefferey Browning4, Samuel Theodore3, Meng Zhang3, Brian Skaug3, Maureen Mayes3 and Shervin Assassi3, 1UTHealth Houston Division of Rheumatology, DeLand, FL, 2University of Texas at Houston McGovern Medical School, Houston, TX, 3UTHealth Houston Division of Rheumatology, Houston, TX, 4Boston Univeristy, Boston, MA

    Background/Purpose: The extent of skin involvement and its rate of progression can provide prognostic information for systemic sclerosis (SSc)-related morbidity and mortality. Moreover, skin assessment…
  • Abstract Number: 2681 • ACR Convergence 2024

    Association of Social Determinants of Health with Systemic Lupus Erythematosus in the United States: Nationally Representative Estimates for 2017-2021

    Ami Vyas, Steven Cohen and Christine Eisenhower, University of Rhode Island, Kingston, RI

    Background/Purpose: Careful assessment of individuals’ social determinants of health (SDOH) that affect systemic lupus erythematosus (SLE) is crucial, as such evidence will improve care and…
  • Abstract Number: 2691 • ACR Convergence 2024

    Transcriptomic Changes in CD4+ T Lymphocytes in Eosinophilic Granulomatosis with Polyangiitis

    Roberto Ríos-Garcés1, Núria Farran1, Salvador Naranjo-Suarez2, Roser Alba-Rovira1, Sergio Prieto-González3, Itziar Tavera-Bahillo1, Roser Solans-Laqué4, Ebymar Arismendi5, Marc Corbera-Bellalta1, Javi Marco-Hernández1, Farah Kamberovic1, Nina Visocnik1, Maria Cid6 and Georgina Espígol-Frigolé1, 1Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, 2Angiogenesis in Liver Disease Research Group, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, 3Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, bar, Spain, 4Internal Medicine Service, Vall d'Hebron Hospital University and Campus, Barcelona, Spain, 5Pneumology Department, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERES, Barcelona, Spain, 6Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain

    Background/Purpose: Eosinophilic Granulomatosis with polyangiitis (EGPA) is a rare systemic autoimmune disorder, included within the ANCA-associated vasculitis. It is characterized by a diverse clinical profile,…
  • Abstract Number: PP16 • ACR Convergence 2024

    Utilization of My Knee Notes for Enhanced Healthcare Management

    Tien Sydnor-Campbell, Medically Retired, Philadelphia, PA

    Background/Purpose: Living with chronic knee issues for 40 years has been incredibly challenging. My knee pain began as early as 6th grade but got overlooked…
  • Abstract Number: 2683 • ACR Convergence 2024

    Optical Coherence Angiography: A Non-invasive, Safe Method for Assessing the Systemic Sclerosis Related Vasculopathy Beyond Nailfold Capillaries

    Pavel Nikitin1, Harshdeep Chawla1, Manmohan Singh1, Samuel Theodore2, Salavat Aglyamov1, Meng Zhang2, Brian Skaug2, Maureen Mayes2, Kirill Larin1 and Shervin Assassi2, 1University of Houston, Houston, TX, 2UTHealth Houston Division of Rheumatology, Houston, TX

    Background/Purpose: Vascular involvement is a prominent feature of systemic sclerosis (SSc). Safe and non-invasive methods to visualize cutaneous blood vessels beyond nailfold capillaries are lacking.…
  • « Previous Page
  • 1
  • …
  • 184
  • 185
  • 186
  • 187
  • 188
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology